Association of Chlamydia pneumoniae IgG and IgA antibody in coronary artery disease

Authors

  • M. Swetha Department of Microbiology, Mysore Medical College & Research Institute, Mysore-570021, Karnataka
  • K. S. Sadananda Associate Professor, Sri. Jayadeva Institute of Cardiovascular Sciences and Research, Mysore-570021, Karnataka
  • D. Venkatesha Department of Microbiology, Mysore Medical College & Research Institute, Mysore-570021, Karnataka
  • K. Anuradha Department of Microbiology, Mysore Medical College & Research Institute, Mysore-570021, Karnataka

Keywords:

Chlamydia pneumoniae, Coronary artery disease

Abstract

Background:Cardiovascular disease, resulting from atherosclerosis, is a leading cause of global morbidity and mortality. Classical risk factors explain much of the attributable risk for cardiovascular events, but other risk factors for the development and progression of atherosclerosis, which can be identified, may be important therapeutic targets. Infectious agents, such as Chlamydia pneumoniae, have been proposed as contributory factors in the pathogenesis of atherosclerosis. The present study was conducted to determine the seroprevalence of C. pneumoniae antibodies and to study the association of chronic C. pneumoniae infection with Coronary Artery Disease (CAD).

Methods:The study group included 90 angiographically proven CAD patients and age and sex matched 90 normal coronaries as control group. With total aseptic precaution 3 ml blood was collected. Enzyme linked immunosorbant assay was performed for all subjects to detect the presence of IgG and IgA antibodies to Chlamydia pneumoniae (Cp).  

Results:IgG and IgA Cp antibodies were detected in 67.8% and 58.9% CAD patients compared to 45.6% and 11.1%   controls. IgG + IgA Cp antibodies were detected in 88.9% CAD patients when compared to 50.0% controls. Seroprevalence of IgG and IgA Cp antibodies were high among CAD patients compared to controls and was found statistically significant. A significant presence of Chlamydia pneumoniae antibodies was detected in smokers, diabetes mellitus, hypertension, and dyslipidemia.  

Conclusion:In the present study, the seroprevalence of IgG and IgA Cp antibodies was found to be higher in CAD patients compared to controls. The present study supports the   association between Chlamydia pneumoniae infection and Coronary artery disease.

 

References

Jha HC, Vardhan H, Gupta R, Varma R, Prasad J, Mittal A. Higher incidence of persistent chronic infection of Chlamydia pneumoniae among coronary artery disease patients in India is a cause of concern. BMC Infect Dis. 2007 May;7:48.

Caroline Watson, Nicholas J. ALP. Role of Chlamydia pneumoniae in atherosclerosis. Clin Sci. 2008;114:509-31.

Haider M, Rizvi M, Malik A, Azam M, Rabbani MU. Acute and chronic Chlamydia pneumoniae infection and inflammatory markers in coronary artery disease patients. J Infect Dev Ctries. 2011;5(8):580-6.

Maryam Ghasemi, Farshad Nagshvar, Said Abedian Kenarii, Asadollah Mohseni Kiasary, Laleh Vahedi Larijani, Nasiri Ebrahim. Association of Chlamydia pneumoniae specific antibody and angiographically demonstrated coronary artery atherosclerosis in a sample of Iranian patients. Res J Biol Sci. 2008;3(2):171-5.

Gupta S, Camm AJ. Chlamydia pneumoniae and coronary heart disease. BMJ. 1997;314:1778-9.

Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA. 2002;288:2724-31.

Mayr M, Metzler B, Kiechl S. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation. 1999;99:1560-6.

Lt Col A. Agarwal, Col Y. Chander, Brig A. Nagendra. Serological evidence of chronic Chlamydia pneumoniae infection in coronary artery disease. Med J Armed Forces India (MJAFI). 2007;63 229-32.

Cook PJ, Honeybourne D. Chlamydia pneumoniae a review. J Antimicrob Chemother. 1994;34:859-73.

Cannon CP, Braunwald E, McCabeC H, Grayston JT, Muhlestein B, Robert P, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005;352:1646-54.

Hahn DL, Golubjatnikov R. Smoking is a potential confounder of the Chlamydia pneumonia: coronary artery disease association. Arterioscler Thromb. 1992;12(8):945-7.

El-Sayed M. Ezzat, Hanan M. El Sayed, Ahmed Amer, Tayseer S. Mohamad, Abdullah A. Ali. Association of Chlamydia pneumoniae Infection with coronary heart disease. Egypt J Med Microbiol. 2006 Oct;15:673.

Danesh J, Wong Y, Ward M, Muir J. Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: population based study of coronary heart disease. Heart. 1999;81:245-7.

Padmavati, Gupta U, Agarwal HK. Chronic infections & coronary artery disease with special reference to Chalmydia pneumoniae. Indian J Med Res. 2012 Feb;135:228-32.

Turkoglu C, Sonmez E, Aydinli A. Relationship between dyslipidemia, C-reactive protein (CRP) and serological evidence of Chlamydia pneumoniae was investigated in a Turkish population with coronary artery disease. N Microbiol. 2004;27(3):229-34.

Murray L, O’Reilly D, Ong G, O’Neill C. A Evans studied Chlamydia pneumoniae antibodies and their association with an atherogenic lipid profile. Heart. 1999 Mar;81(3):239-44

Jaremo P, Richter A. Chlamydia pneumoniae IgG and the severity of coronary atherosclerosis. Eur J Intern Med. 2004 Dec;15:508-10.

Falck G, Gnarpe J, Hansson LO, Svardsudd K. Comparison of individuals with and without specific IgA antibodies to Chlamydia pneumoniae: respiratory morbidity and the metabolic syndrome. Chest. 2002;122(5):1587-93.

Mandell GL, Bennett JE, Raphael D. Chlamydia pneumoniae infection and CAD. In: Mandell GL, Bennett JE, Raphael D, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2005: 2258-2265.

Mazzoli S, Tofani N, Fantini A, Semplici F, Bandini F, Salvi A, et al. Chlamydia pneumoniae antibody response in patients with acute myocardial infarction and their follow-up. Am Heart J. 1998 Jan;135(1):15-20.

Leowattana W, Mahanonda N, Bhuripanyo K, Pokium S, Kiartivich S. Chlamydia pneumoniae antibodies and angiographically demonstrated coronary artery disease in Thailand. J Med Assoc Thai. 2000 Sep;83(9):1054-8.

Masato Nishimura, Tet Suya Hashimoto, Hiroyuki Kobayashi. Close association of C. pneumoniae IgA seropositivity by ELISA with the presence of coronary artery stenosis in hemodialysis patients. Nephrol Dialysis Transplant. 2005;20(9):1944-50.

Badiaga S, Paganel F, Parola P, Beghin M, Barrau K, Eb F, et al. Chlamydia pneumoniae, but not Bartonella quintana, is associated with coronary heart disease: results of a French case-control study. Clin Microbiol Infect. 2003;9(4):315-8.

Downloads

Published

2017-01-05

How to Cite

Swetha, M., Sadananda, K. S., Venkatesha, D., & Anuradha, K. (2017). Association of Chlamydia pneumoniae IgG and IgA antibody in coronary artery disease. International Journal of Research in Medical Sciences, 3(1), 156–160. Retrieved from https://www.msjonline.org/index.php/ijrms/article/view/1224

Issue

Section

Original Research Articles